+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Histone Deacetylase Inhibitors Market Research Report by Class (Class I HDACs, Class II HDACs, and Class III HDACs), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5532783
  • Report
  • April 2022
  • Region: Global
  • 219 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AstraZeneca PLC
  • Celgene Corporation
  • Eisai Co., Ltd.
  • MEI Pharma Inc.
  • Midatech Pharma PLC
  • Oncolys BioPharma Inc.
The Global Histone Deacetylase Inhibitors Market size was estimated at USD 13.25 billion in 2021, USD 14.75 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 11.54% to reach USD 25.53 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Histone Deacetylase Inhibitors to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Class, the market was studied across Class I HDACs, Class II HDACs, and Class III HDACs.
  • Based on Application, the market was studied across Central Nervous System Disorders, Neurology, and Oncology.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Histone Deacetylase Inhibitors market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Histone Deacetylase Inhibitors Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Histone Deacetylase Inhibitors Market, including Acetylon Pharmaceuticals, Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., EnVivo Pharmaceuticals, Inc., Evgen Pharma, FORUM Pharmaceuticals Inc., Karyopharm Therapeutics Inc., MEI Pharma Inc., Merck & Co., Inc., Midatech Pharma PLC, Novartis International AG, Oncolys BioPharma Inc., Pfizer Inc., Regenacy Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., and Syndax Pharmaceuticals Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Histone Deacetylase Inhibitors Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Histone Deacetylase Inhibitors Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Histone Deacetylase Inhibitors Market?
4. What is the competitive strategic window for opportunities in the Global Histone Deacetylase Inhibitors Market?
5. What are the technology trends and regulatory frameworks in the Global Histone Deacetylase Inhibitors Market?
6. What is the market share of the leading vendors in the Global Histone Deacetylase Inhibitors Market?
7. What modes and strategic moves are considered suitable for entering the Global Histone Deacetylase Inhibitors Market?
Frequently Asked Questions about the Global Histone Deacetylase Inhibitors Market

What is the estimated value of the Global Histone Deacetylase Inhibitors Market?

The Global Histone Deacetylase Inhibitors Market was estimated to be valued at $13.3 Billion in 2021.

What is the growth rate of the Global Histone Deacetylase Inhibitors Market?

The growth rate of the Global Histone Deacetylase Inhibitors Market is 11.5%, with an estimated value of $25.5 Billion by 2027.

What is the forecasted size of the Global Histone Deacetylase Inhibitors Market?

The Global Histone Deacetylase Inhibitors Market is estimated to be worth $25.5 Billion by 2027.

Who are the key companies in the Global Histone Deacetylase Inhibitors Market?

Key companies in the Global Histone Deacetylase Inhibitors Market include Acetylon Pharmaceuticals, Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., EnVivo Pharmaceuticals, Inc., Evgen Pharma and Karyopharm Therapeutics Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca PLC
  • Celgene Corporation
  • Eisai Co., Ltd.
  • MEI Pharma Inc.
  • Midatech Pharma PLC
  • Oncolys BioPharma Inc.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of cancer coupled with need for effective treatment therapies
5.1.1.2. Increasing application in prognosis, treatment and diagnosis of chronic diseases
5.1.1.3. Rising demand from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
5.1.2. Restraints
5.1.2.1. Dearth of awareness among people and lack of reimbursement policies
5.1.2.2. High cost of raw material and lack of trained professionals
5.1.3. Opportunities
5.1.3.1. Rising adoption of advanced technologies and collaboration among manufacturers and companies
5.1.3.2. Increasing investment for drug development from government and private organizations
5.1.4. Challenges
5.1.4.1. Strict mandates for the production and probable side effects such as toxicity
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Histone Deacetylase Inhibitors Market, by Class
6.1. Introduction
6.2. Class I HDACs
6.3. Class II HDACs
6.4. Class III HDACs
7. Histone Deacetylase Inhibitors Market, by Application
7.1. Introduction
7.2. Central Nervous System Disorders
7.3. Neurology
7.4. Oncology
8. Americas Histone Deacetylase Inhibitors Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Histone Deacetylase Inhibitors Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Histone Deacetylase Inhibitors Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Acetylon Pharmaceuticals, Inc.
12.2. AstraZeneca PLC
12.3. Aurobindo Pharma Limited
12.4. Celgene Corporation
12.5. Celleron Therapeutics Ltd
12.6. Eisai Co., Ltd.
12.7. EnVivo Pharmaceuticals, Inc.
12.8. Evgen Pharma
12.9. FORUM Pharmaceuticals Inc.
12.10. Karyopharm Therapeutics Inc.
12.11. MEI Pharma Inc.
12.12. Merck & Co., Inc.
12.13. Midatech Pharma PLC
12.14. Novartis International AG
12.15. Oncolys BioPharma Inc.
12.16. Pfizer Inc.
12.17. Regenacy Pharmaceuticals, Inc.
12.18. Shenzhen Chipscreen Biosciences Co., Ltd.
12.19. Spectrum Pharmaceuticals, Inc.
12.20. Syndax Pharmaceuticals Inc.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: DYNAMICS
FIGURE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2021 VS 2027 (%)
FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2027
FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2027
FIGURE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2019-2027 (USD BILLION)
FIGURE 15. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 16. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 21. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 22. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 23. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 24. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 25. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 26. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 27. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 28. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 32. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 33. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: FPNV POSITIONING MATRIX
FIGURE 51. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 52. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 20. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019-2027 (USD BILLION)
TABLE 21. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 22. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY STATE, 2019-2027 (USD BILLION)
TABLE 23. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 36. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 37. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 38. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 39. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 40. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 41. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 42. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 43. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 44. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 45. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 46. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 47. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 48. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 49. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 50. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 51. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 52. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 54. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 55. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 56. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 57. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 58. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 59. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 60. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 61. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: SCORES
TABLE 66. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: BUSINESS STRATEGY
TABLE 67. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: PRODUCT SATISFACTION
TABLE 68. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: RANKING
TABLE 69. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 70. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: MERGER & ACQUISITION
TABLE 71. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 72. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 73. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: INVESTMENT & FUNDING
TABLE 74. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 75. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Acetylon Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Celgene Corporation
  • Celleron Therapeutics Ltd
  • Eisai Co., Ltd.
  • EnVivo Pharmaceuticals, Inc.
  • Evgen Pharma
  • FORUM Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • MEI Pharma Inc.
  • Merck & Co., Inc.
  • Midatech Pharma PLC
  • Novartis International AG
  • Oncolys BioPharma Inc.
  • Pfizer Inc.
  • Regenacy Pharmaceuticals, Inc.
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Syndax Pharmaceuticals Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...